politics
Senate bill would cap insulin costs at $35 for privately insured patients
Bipartisan legislation in the Senate would limit out-of-pocket insulin costs to $35 per month for people with commercial insurance. The measure would also create a pilot program in ten states for uninsured patients.
usatoday.comAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
Bipartisan legislation advancing in the Senate would cap monthly out-of-pocket insulin costs at $35 for people with commercial health insurance. The bill would also establish a pilot program in ten states to limit costs for uninsured patients. Sens.
) are co-sponsors. Twenty-eight senators now back the measure, split evenly between the parties.
Committee action The Senate HELP Committee approved the insulin provision last week as an amendment during markup of another bill. The committee voted 15-8, with all Democratic members and some Republicans in favor. Committee chairman Sen. ) voted against the amendment.
He said it was not germane to the underlying bill and raised concerns about cost and overlap with existing programs.
Background and polling A $35 monthly cap for Medicare beneficiaries was enacted in the Inflation Reduction Act of 2022. Some drugmakers have also voluntarily limited insulin prices. A poll by the American Diabetes Association found that 40 percent of insulin users pay more than $150 per month and that 76 percent of respondents across parties support a $35 limit.
